Loading...

Atossa Genetics

Nasdaq:ATOS
Snowflake Description

Flawless balance sheet with moderate growth potential.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
ATOS
Nasdaq
$32M
Market Cap
  1. Home
  2. US
  3. Healthcare
Company description

Atossa Genetics Inc. a clinical-stage pharmaceutical company, focuses on the development and sale of novel therapeutics and delivery methods for the treatment of breast cancer and other breast conditions in the United States. The last earnings update was 27 days ago. More info.


Add to Portfolio Compare Print
  • Atossa Genetics has significant price volatility in the past 3 months.
ATOS Share Price and Events
7 Day Returns
32.8%
NasdaqCM:ATOS
-5.3%
US Medical Equipment
-0.1%
US Market
1 Year Returns
-6.5%
NasdaqCM:ATOS
12.4%
US Medical Equipment
7.6%
US Market
ATOS Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Atossa Genetics (ATOS) 32.8% -8.9% 159.2% -6.5% -94.3% -98.4%
US Medical Equipment -5.3% -5.8% 2.1% 12.4% 49.3% 90.1%
US Market -0.1% 3.7% 10.2% 7.6% 38.1% 46.4%
1 Year Return vs Industry and Market
  • ATOS underperformed the Medical Equipment industry which returned 12.4% over the past year.
  • ATOS underperformed the Market in United States of America which returned 7.6% over the past year.
Price Volatility
ATOS
Industry
5yr Volatility vs Market

Value

 Is Atossa Genetics undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Atossa Genetics. This is due to cash flow or dividend data being unavailable. The share price is $3.48.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Atossa Genetics's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Atossa Genetics's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
NasdaqCM:ATOS PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in USD $-5.50
NasdaqCM:ATOS Share Price ** NasdaqCM (2019-04-23) in USD $3.48
United States of America Medical Equipment Industry PE Ratio Median Figure of 63 Publicly-Listed Medical Equipment Companies 38.8x
United States of America Market PE Ratio Median Figure of 3,080 Publicly-Listed Companies 18.03x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Atossa Genetics.

NasdaqCM:ATOS PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqCM:ATOS Share Price ÷ EPS (both in USD)

= 3.48 ÷ -5.50

-0.63x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Atossa Genetics is loss making, we can't compare its value to the US Medical Equipment industry average.
  • Atossa Genetics is loss making, we can't compare the value of its earnings to the United States of America market.
Price based on expected Growth
Does Atossa Genetics's expected growth come at a high price?
Raw Data
NasdaqCM:ATOS PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -0.63x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 3 Analysts
56.7%per year
United States of America Medical Equipment Industry PEG Ratio Median Figure of 54 Publicly-Listed Medical Equipment Companies 2.3x
United States of America Market PEG Ratio Median Figure of 2,109 Publicly-Listed Companies 1.55x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Atossa Genetics, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Atossa Genetics's assets?
Raw Data
NasdaqCM:ATOS PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in USD $1.10
NasdaqCM:ATOS Share Price * NasdaqCM (2019-04-23) in USD $3.48
United States of America Medical Equipment Industry PB Ratio Median Figure of 184 Publicly-Listed Medical Equipment Companies 4.14x
United States of America Market PB Ratio Median Figure of 5,185 Publicly-Listed Companies 1.92x
NasdaqCM:ATOS PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqCM:ATOS Share Price ÷ Book Value per Share (both in USD)

= 3.48 ÷ 1.10

3.17x

* Primary Listing of Atossa Genetics.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Atossa Genetics is good value based on assets compared to the US Medical Equipment industry average.
X
Value checks
We assess Atossa Genetics's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Medical Equipment industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Medical Equipment industry average (and greater than 0)? (1 check)
  5. Atossa Genetics has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Atossa Genetics expected to perform in the next 1 to 3 years based on estimates from 3 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
56.7%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Atossa Genetics expected to grow at an attractive rate?
  • Atossa Genetics's earnings growth is expected to exceed the low risk savings rate of 2.7%.
Growth vs Market Checks
  • Atossa Genetics's earnings growth is expected to exceed the United States of America market average.
  • Unable to compare Atossa Genetics's revenue growth to the United States of America market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
NasdaqCM:ATOS Future Growth Rates Data Sources
Data Point Source Value (per year)
NasdaqCM:ATOS Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 3 Analysts 56.7%
United States of America Medical Equipment Industry Earnings Growth Rate Market Cap Weighted Average 20.8%
United States of America Medical Equipment Industry Revenue Growth Rate Market Cap Weighted Average 7.8%
United States of America Market Earnings Growth Rate Market Cap Weighted Average 13.5%
United States of America Market Revenue Growth Rate Market Cap Weighted Average 7.1%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
NasdaqCM:ATOS Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
NasdaqCM:ATOS Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 133 66 1
2022-12-31 94 41 1
2021-12-31 48 11 1
2020-12-31 1 -17 3
2019-12-31 0 -17 3
NasdaqCM:ATOS Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2018-12-31 -9 -23
2018-09-30 -8 -23
2018-06-30 -8 -22
2018-03-31 -7 -11
2017-12-31 -7 -11
2017-09-30 -6 -11
2017-06-30 -4 -9
2017-03-31 -4 -6
2016-12-31 -5 -6
2016-09-30 0 -8 -6
2016-06-30 0 -12 -10
2016-03-31 0 -14 -12

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Atossa Genetics's earnings are expected to grow significantly at over 20% yearly.
  • Unable to determine if Atossa Genetics is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
NasdaqCM:ATOS Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below

All data from Atossa Genetics Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqCM:ATOS Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31 3.75 3.75 3.75 1.00
2022-12-31 2.33 2.33 2.33 1.00
2021-12-31 0.67 0.67 0.67 1.00
2020-12-31 -1.64 -0.97 -2.25 3.00
2019-12-31 -2.19 -1.88 -2.81 3.00
NasdaqCM:ATOS Past Financials Data
Date (Data in USD Millions) EPS *
2018-12-31 -5.50
2018-09-30 -7.09
2018-06-30 -9.98
2018-03-31 -6.97
2017-12-31 -10.97
2017-09-30 -19.62
2017-06-30 -23.42
2017-03-31 -20.90
2016-12-31 -25.93
2016-09-30 -29.65
2016-06-30 -54.85
2016-03-31 -68.29

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Atossa Genetics will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Atossa Genetics's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Atossa Genetics has a total score of 3/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Atossa Genetics performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Atossa Genetics's growth in the last year to its industry (Medical Equipment).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Atossa Genetics does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Atossa Genetics's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Atossa Genetics's 1-year growth to the US Medical Equipment industry average as it is not currently profitable.
Earnings and Revenue History
Atossa Genetics's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Atossa Genetics Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqCM:ATOS Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 -22.88 7.22 4.21
2018-09-30 -22.80 7.28 3.58
2018-06-30 -21.67 6.71 2.90
2018-03-31 -10.86 5.10 2.25
2017-12-31 -10.69 4.86 2.33
2017-09-30 -11.22 4.98 2.48
2017-06-30 -8.83 4.98 1.82
2017-03-31 -5.74 5.46 1.16
2016-12-31 -6.37 6.48 0.77
2016-09-30 0.00 -6.44 6.91 0.88
2016-06-30 0.00 -10.41 8.50 1.74
2016-03-31 0.00 -11.81 9.74 1.94
2015-12-31 0.00 -12.76 10.27 2.36
2015-09-30 0.00 -13.49 10.12 1.14
2015-06-30 0.01 -12.97 9.55 1.12
2015-03-31 0.02 -13.03 9.44 1.25
2014-12-31 0.04 -12.17 8.75 1.11
2014-09-30 0.08 -11.60 9.49 2.02
2014-06-30 0.16 -11.86 10.39 1.41
2014-03-31 0.47 -11.25 10.25 1.09
2013-12-31 0.63 -10.78 10.03 0.89
2013-09-30 0.68 -9.73 8.86 1.15
2013-06-30 0.71 -7.37 6.31 1.37
2013-03-31 0.61 -5.96 4.59 1.77
2012-12-31 0.48 -5.08 3.48 1.92
2012-09-30 0.38 -4.58 3.21 1.51
2012-06-30 0.28 -4.66 3.76 0.96

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Atossa Genetics has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Atossa Genetics has efficiently used its assets last year compared to the US Medical Equipment industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Atossa Genetics improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Atossa Genetics's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Medical Equipment industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Atossa Genetics has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Atossa Genetics's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Atossa Genetics's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Atossa Genetics is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Atossa Genetics has no long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Atossa Genetics's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Atossa Genetics has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Atossa Genetics Company Filings, last reported 3 months ago.

NasdaqCM:ATOS Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 8.81 0.00 10.38
2018-09-30 10.57 0.00 12.94
2018-06-30 13.57 0.00 15.24
2018-03-31 5.26 0.00 4.78
2017-12-31 6.94 0.00 7.22
2017-09-30 2.56 0.00 2.73
2017-06-30 2.80 0.00 3.69
2017-03-31 1.53 0.00 1.17
2016-12-31 3.10 0.00 3.03
2016-09-30 5.41 0.00 4.39
2016-06-30 2.41 0.00 1.19
2016-03-31 3.77 0.00 2.88
2015-12-31 3.74 0.00 3.72
2015-09-30 9.06 0.00 7.84
2015-06-30 13.12 0.08 11.40
2015-03-31 10.28 0.11 9.73
2014-12-31 9.50 0.00 8.50
2014-09-30 15.23 0.00 11.37
2014-06-30 18.26 0.00 14.30
2014-03-31 21.30 0.00 16.59
2013-12-31 10.60 0.02 6.34
2013-09-30 11.54 0.00 7.69
2013-06-30 8.28 0.00 2.44
2013-03-31 6.98 0.00 1.39
2012-12-31 5.18 0.00 1.73
2012-09-30 3.40 0.33 0.42
2012-06-30 -0.56 0.25 0.09
  • Atossa Genetics has no debt.
  • Atossa Genetics has no debt compared to 5 years ago when it was 0.1%.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Atossa Genetics has sufficient cash runway for 1.1 years based on current free cash flow.
  • Atossa Genetics has sufficient cash runway for 1.2 years if free cash flow continues to reduce at historical rates of -20.2% each year.
X
Financial health checks
We assess Atossa Genetics's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Atossa Genetics has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Atossa Genetics's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Atossa Genetics dividends.
If you bought $2,000 of Atossa Genetics shares you are expected to receive $0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Atossa Genetics's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Atossa Genetics's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
NasdaqCM:ATOS Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below
United States of America Medical Equipment Industry Average Dividend Yield Market Cap Weighted Average of 24 Stocks 1.3%
United States of America Market Average Dividend Yield Market Cap Weighted Average of 2008 Stocks 2.4%
United States of America Minimum Threshold Dividend Yield 10th Percentile 0.8%
United States of America Bottom 25% Dividend Yield 25th Percentile 1.4%
United States of America Top 25% Dividend Yield 75th Percentile 3.6%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

NasdaqCM:ATOS Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31
2020-12-31
2019-12-31

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Atossa Genetics has not reported any payouts.
  • Unable to verify if Atossa Genetics's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Atossa Genetics's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Atossa Genetics has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Atossa Genetics's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Atossa Genetics afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Atossa Genetics has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Atossa Genetics's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Steve Quay
COMPENSATION $1,019,736
AGE 67
TENURE AS CEO 10 years
CEO Bio

Dr. Steven C. Quay, also known as Steve, M.D., Ph.D., FCAP has been the Chief Executive Officer and President of Atossa Genetics, Inc. since April 30, 2009 and served as its Chief Financial Officer since April 30, 2009. Dr. Quay also served as Treasurer of Atossa Genetics, Inc. and served as its Corporate Secretary and Chief Accounting Officer. He served as the Chief Scientific Officer of MDRNA, Inc. from June 23, 2008 to November 30, 2008. Dr. Quay served as the Chief Executive Officer of MDRNA, Inc. from August 2000 to June 23, 2008 and also served as its President from August 2000 to December 20, 2007. He served as the Chief Executive Officer of Nycomed Salutar, Inc. He founded Atossa Healthcare Inc. in 1999 and Salutar, Inc. in 1984. Dr. Quay served as the Chairman of the Board, President and Chief Executive Officer of Atossa Healthcare Inc. Dr. Quay Founded SONUS Pharmaceuticals, Inc., in 1991 where he served as Chief Executive Officer, President and a Director until June 1999. Dr. Quay serves as Chairman of Atossa Genetics, Inc. Dr. Quay served as Chairman of the Board of MDRNA, Inc. from August 2000 to November 30, 2008. He served as Chairman of the Scientific Advisory Board of MDRNA, Inc. from June 23, 2008 to November 30, 2008. Dr. Quay has been a Director of Atossa Genetics, Inc. since April 30, 2009. Dr. Quay serves as a Director of VitalMedix Inc. Dr. Quay served as Director of MDRNA, Inc. from August 2000 to May 20, 2009 and its Member of the Scientific Advisory Board from June 23, 2008 to May 20, 2009. From 1980 to 1986, he served as a Faculty Member at Stanford University School of Medicine. Dr. Quay serves as a Member of numerous professional societies, including the American Medical Association, the American Society for Biochemistry and Molecular biology, the Society of Magnetic Resonance in Medicine, the American Society for Echo cardiology and the American Institute for Ultrasound Medicine. He has 135 scientific publications, 67 patents and is a board-certified pathologist. Dr. Quay graduated from the University of Michigan Medical School, where he received an M.D., M.A. and Ph.D. in Biological Chemistry in 1977, 1974 and 1975, respectively. Dr. Quay did Post-Graduate work in the Chemistry department at the Massachusetts Institute of Technology and received his Residency training at the Massachusetts General Hospital, Harvard Medical School. He holds BA in Chemistry and mathematics from Michigan University.

CEO Compensation
  • Steve's compensation has increased whilst company is loss making.
  • Steve's remuneration is higher than average for companies of similar size in United States of America.
Management Team Tenure

Average tenure of the Atossa Genetics management team in years:

4.3
Average Tenure
  • The tenure for the Atossa Genetics management team is about average.
Management Team

Steve Quay

TITLE
Chairman
COMPENSATION
$1M
AGE
67
TENURE
10 yrs

Kyle Guse

TITLE
CFO, General Counsel & Secretary
COMPENSATION
$736K
AGE
54
TENURE
6.3 yrs

Janet Rea

TITLE
Senior Vice President of Regulatory
TENURE
1.3 yrs

Jack Cuzick

TITLE
Member of Scientific Advisory Board
TENURE
2.3 yrs
Board of Directors Tenure

Average tenure and age of the Atossa Genetics board of directors in years:

5.3
Average Tenure
64
Average Age
  • The tenure for the Atossa Genetics board of directors is about average.
Board of Directors

Stephen Galli

TITLE
Independent Director
COMPENSATION
$90K
AGE
71
TENURE
7.8 yrs

Steve Quay

TITLE
Chairman
COMPENSATION
$1M
AGE
67
TENURE
10 yrs

Greg Weaver

TITLE
Director
COMPENSATION
$91K
AGE
62
TENURE
5.5 yrs

Rich Steinhart

TITLE
Director
COMPENSATION
$89K
AGE
61
TENURE
5.1 yrs

Shu-Chih Chen

TITLE
Director
COMPENSATION
$63K
AGE
56
TENURE
10 yrs

Larry Remmel

TITLE
Independent Director
COMPENSATION
$22K
AGE
66
TENURE
7.2 yrs

Jack Cuzick

TITLE
Member of Scientific Advisory Board
TENURE
2.3 yrs

Carl Novina

TITLE
Scientific Advisor
TENURE
1.3 yrs

Per Hall

TITLE
Scientific Advisor
TENURE
1.1 yrs

Bob Miglani

TITLE
Member of Strategic Advisory Board
TENURE
0.9 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price ($) Value ($)
X
Management checks
We assess Atossa Genetics's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Atossa Genetics has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

What Kind Of Investor Owns Most Of Atossa Genetics Inc. (NASDAQ:ATOS)?

Large companies usually have institutions as shareholders, and we usually see insiders owning shares in smaller companies. … Atossa Genetics is a smaller company with a market capitalization of US$8.5m, so it may still be flying under the radar of many institutional investors. … institutions own shares in the company.

Simply Wall St -

Is It Too Late To Buy Atossa Genetics Inc (NASDAQ:ATOS)?

Atossa Genetics Inc (NASDAQ:ATOS), a medical equipment company based in United States,. … As a small cap stock, which tends to lack high analyst coverage, there is generally more of an opportunity for mispricing as there is less activity to push the stock closer to fair value? … Let’s examine Atossa Genetics’s valuation and outlook in more detail to determine if there’s still a bargain opportunity

Simply Wall St -

When Can We Expect A Profit From Atossa Genetics Inc (NASDAQ:ATOS)?

Atossa Genetics Inc's (NASDAQ:ATOS):. … The US$7.60m market-cap posted a loss in its most recent financial year of -US$10.69m and a latest trailing-twelve-month loss of -US$10.86m leading to an even wider gap between loss and breakeven? … In this article, I will touch on the expectations for ATOS’s growth and when analysts expect the company to become profitable

Simply Wall St -

Market Sentiment Around Loss-Making Atossa Genetics Inc (NASDAQ:ATOS)

In this article, I will touch on the expectations for ATOS’s growth and when analysts expect the company to become profitable. … NasdaqCM:ATOS Past Future Earnings May 17th 18 Given this is a high-level overview, I won’t go into detail the detail of ATOS’s upcoming projects, though, keep in mind that typically a high forecast growth rate is not unusual for a company that is currently undergoing an investment period. … ATOS currently has no debt on its balance sheet, which is quite unusual for a cash-burning loss-making, growth company, which usually has a high level of debt relative to its equity.

Simply Wall St -

Should Atossa Genetics Inc's (NASDAQ:ATOS) Recent Earnings Decline Worry You?

NasdaqCM:ATOS Income Statement Apr 25th 18 We can further analyze Atossa Genetics's loss by looking at what the industry has been experiencing over the past few years. … This shows that any tailwind the industry is profiting from, Atossa Genetics has not been able to reap as much as its industry peers.What does this mean? … You should continue to research Atossa Genetics to get a more holistic view of the stock by looking at: Future Outlook: What are well-informed industry analysts predicting for ATOS’s future growth?

Simply Wall St -

Will Atossa Genetics Inc's (NASDAQ:ATOS) Earnings Grow Over The Next Few Years?

In December 2017, Atossa Genetics Inc (NASDAQ:ATOS) released its latest earnings announcement, which suggested company earnings became less negative compared to the previous year's level - great news for investors Below, I've presented key growth figures on how market analysts perceive Atossa Genetics's earnings growth outlook over the next few years and whether the future looks brighter. … Check out our latest analysis for Atossa Genetics Market analysts' consensus outlook for next year seems relatively subdued, with earnings continuing to flop around in the negative territory, reaching -US$10.67M in 2019. … This means that, we can assume Atossa Genetics will grow its earnings by 25.97% every year for the next few years.

Simply Wall St -

Should You Buy Atossa Genetics Inc (NASDAQ:ATOS) Now?

Let’s take a look at Atossa Genetics’s outlook and value based on the most recent financial data to see if the opportunity still exists. … Great news for investors – Atossa Genetics is still trading at a fairly cheap price. … What’s more interesting is that, Atossa Genetics’s share price is quite volatile, which gives us more chances to buy since the share price could sink lower (or rise higher) in the future.

Simply Wall St -

Who Really Owns Atossa Genetics Inc (NASDAQ:ATOS)?

This size of ownership gives retail investors collective power in deciding on major policy decisions such as executive compensation, appointment of directors and acquisitions of businesses. … This level of ownership gives retail investors the power to sway key policy decisions such as board composition, executive compensation, and potential acquisitions. … Thus, investors not need worry too much about the consequences of these holdings.Next Steps: While institutional ownership in ATOS is low, active hedge funds still have a significant stake in the company.

Simply Wall St -

Is This A Catalyst To Buy Atossa Genetics Inc (NASDAQ:ATOS)?

NasdaqCM:ATOS Income Statement Jan 31st 18 When will Atossa Genetics need to raise more cash? … In Atossa Genetics’s case, its opex fell by 1.33% last year, which may signal the company moving towards a more sustainable level of expenses. … However, even with declining costs, the current level of cash is not enough to sustain Atossa Genetics’s operations and the company may need to come to market to raise more capital within the year.

Simply Wall St -

What Are The Drivers Of Atossa Genetics Inc's (NASDAQ:ATOS) Risks?

Based on this beta value, ATOS may be a stock for investors with a portfolio mainly made up of low-beta stocks. … ATOS, with its market capitalisation of $10.35M, is a small-cap stock, which generally have higher beta than similar companies of larger size. … Thus, we can expect ATOS to be more stable in the face of market movements, relative to its peers of similar size but with a higher portion of fixed assets on their books.

Simply Wall St -

Company Info

Description

Atossa Genetics Inc. a clinical-stage pharmaceutical company, focuses on the development and sale of novel therapeutics and delivery methods for the treatment of breast cancer and other breast conditions in the United States. The company is conducting a Phase 2 clinical study using microcatheters to deliver fulvestrant as a potential treatment of ductal carcinoma in situ and breast cancer; and a pharmaceutical program under development is Endoxifen, an active metabolite of tamoxifen, as well as treatment for breast density and other breast health conditions. It offers ForeCYTE Breast Aspirator and FullCYTE Breast Aspirator, which collects specimens of nipple aspirate fluid (NAF)for cytological testing at a laboratory; and a transport kit to assist with the packaging and transport of NAF samples to a laboratory, as well as manufactures and sells various medical devices primarily consisting of tools to assist breast surgeons. Atossa Genetics Inc. was founded in 2009 and is headquartered in Seattle, Washington.

Details
Name: Atossa Genetics Inc.
ATOS
Exchange: NasdaqCM
Founded: 2009
$31,753,075
9,124,447
Website: http://www.atossagenetics.com
Address: Atossa Genetics Inc.
107 Spring Street,
Seattle,
Washington, 98104,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqCM ATOS Common Stock Nasdaq Capital Market US USD 08. Nov 2012
DB YAG2 Common Stock Deutsche Boerse AG DE EUR 08. Nov 2012
BST YAG2 Common Stock Boerse-Stuttgart DE EUR 08. Nov 2012
Number of employees
Current staff
Staff numbers
5
Atossa Genetics employees.
Industry
Health Care Equipment
Healthcare
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/24 00:37
End of day share price update: 2019/04/23 00:00
Last estimates confirmation: 2019/04/18
Last earnings filing: 2019/03/28
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.